ASX:ACWBiotechs
Actinogen Medical H1 2026 Wider A$17.9m TTM Loss Reinforces Bearish Narratives
Actinogen Medical (ASX:ACW) has reported its H1 2026 numbers with trailing twelve month revenue of A$7.4 million and a basic EPS loss of A$0.0058 per share, keeping the focus firmly on how much cash the business is consuming rather than generating. The company has seen reported half year revenue move between A$9.0 million in H2 2024, A$0 in H1 2025 and A$5.5 million in H2 2025, alongside basic EPS losses of A$0.0007, A$0.0028 and A$0.0022 respectively, so investors are likely to be weighing...